Industry
Biotechnology
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Loading...
Open
0.82
Mkt cap
12M
Volume
274K
High
0.84
P/E Ratio
-0.42
52-wk high
3.65
Low
0.79
Div yield
N/A
52-wk low
0.48
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 10:47 am
Portfolio Pulse from Henry Khederian
July 31, 2024 | 7:32 pm
Portfolio Pulse from Avi Kapoor
July 31, 2024 | 7:02 pm
Portfolio Pulse from Avi Kapoor
July 31, 2024 | 4:45 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:27 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:15 pm
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 6:31 pm
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 5:53 pm
Portfolio Pulse from Vandana Singh
July 30, 2024 | 5:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.